Fundraising FoxSanderling Ventures — 2017 Investments
2 investments dated 2017 · listed companies and verified rows first · show all
Metavention is developing a treatment that targets the sympathetic nervous system to disrupt overactive nerves believed to contribute to high blood pressure and other metabolic diseases.
BiotechHealthtechMedical DevicesEden Prairie, US
Bobak Azamian(Executive Officer, Director)Tony Vrba(Executive Officer)Kevin Hykes(Executive Officer, Director)Kirk Nielsen(Director)in
Co-investorsNew Enterprise Associates (NEA)Vensana CapitalVersant Ventures
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.